US Pharma MarketingThe post AstraZeneca trips in PD-1 bispecific market after Phase III NSCLC failure appeared first on Clinical Trials Arena.
AstraZeneca trips in PD-1 bispecific market after Phase III NSCLC failure
In August, AstraZeneca discontinued the eVOLVE-Lung02 Phase III trial of volrustomig in combination with chemotherapy in first-line mNSCLC. The post AstraZeneca trips in PD-1 bispecific market after Phase III NSCLC failure appeared first on Clinical Trials Arena .
In August, AstraZeneca discontinued the eVOLVE-Lung02 Phase III trial of volrustomig in combination with chemotherapy in first-line mNSCLC.
Source: Clinical Trials Arena